Synergistic inhibition effect of tumor growth by using celecoxib in combination with oxaliplatin.
BACKGROUND
To evaluate the effects of celecoxib, in combination with oxaliplatin, on tumour growth, cell apoptosis and angiogenesis in nude mice models.


METHODS
Xenograft mice model of colon cancer was established using the BALB/c nude mice. Medicine was administered respectively in different groups. Tumour volumes, the expression level of survivin, beta-catenin, VEGF mRNA level, the microvessel density and cell apoptosis were measured.


RESULTS
Celecoxib, oxaliplatin and combination use caused a tumour inhibition of 35%, 31% and 63% respectively. Compared with control group, a significant redation of angiogenesis and the levels of COX-2, survivin and beta-cantenin protein, and increase of cell apoptosis were detected in tumors in celecoxib group. Celecoxib in combination with oxaliplatin could further promote cell apoptosis and reduce beta-catenin protein expression.


CONCLUSIONS
Celecoxib could inhibit tumor growth and enhance the antitumor effects of oxaliplatin through their synergistic role in inhibiting different targets.
Zhao
Shipeng
S
Department of Coloproctology, Third Hospital of Hebei Medical University, Shijiazhuang HeBei, China. shipengzcn@yahoo.com.cn
Cai
Jianhui
J
Bian
Honglei
H
Gui
Lin
L
Zhao
Fa
F
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D000068579:Celecoxib; D049109:Cell Proliferation / Q000187:drug effects*; D003110:Colonic Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D051546:Cyclooxygenase 2 / Q000378:metabolism; D052246:Cyclooxygenase 2 Inhibitors / Q000494:pharmacology; D004357:Drug Synergism; D019073:HT29 Cells; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D008869:Microtubule-Associated Proteins / Q000378:metabolism; D009389:Neovascularization, Pathologic / Q000517:prevention & control; D009944:Organoplatinum Compounds / Q000494:pharmacology; D000077150:Oxaliplatin; D011720:Pyrazoles / Q000494:pharmacology; D012333:RNA, Messenger / Q000378:metabolism; D013449:Sulfonamides / Q000494:pharmacology; D000077022:Survivin; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism; D023041:Xenograft Model Antitumor Assays; D051176:beta Catenin / Q000378:metabolism
C107489:BIRC5 protein, human; C495270:CTNNB1 protein, human; D052246:Cyclooxygenase 2 Inhibitors; D051034:Inhibitor of Apoptosis Proteins; D008869:Microtubule-Associated Proteins; D009944:Organoplatinum Compounds; D011720:Pyrazoles; D012333:RNA, Messenger; D013449:Sulfonamides; D000077022:Survivin; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D051176:beta Catenin; D000077150:Oxaliplatin; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D000068579:Celecoxib